Case Report : Expanded-Spectrum Beta Lactamase-Producing Klebsiella pneumoniae in Burn Injury With Hospital Acquired Pneumonia
DOI:
https://doi.org/10.21776/ub.pji.2020.005.02.2Keywords:
Acinetobacter baumanii, Hospital Acquired Pneumonia, Klebseilla pneumonia ESBL, Levofloxacin, MeropenemAbstract
Significantly higher mortality has been demonstrated in patients with severe burn, complicated by Klebsiella pneumonia infection. This case report assesses the efficacy combination of meropenem and levofloxacin to treat Klebsiella pneumonia ESBL on the scald-burn injury with hospital-acquired pneumonia. A 52-year-old male had scald burn on August, 2016 with late onset of Hospital Acquired Pneumonia (HAP). Klebsiella pneumonia ESBL was isolated from tissue burned culture. Initially, the patient was treated with meropenem and levofloxacin injection for a week. Then, Acinetobacter baumanii was isolated from tissue burned infection and ampicilin-sulbactam was the only one antibiotic which still susceptible to this pathogen. But with the clinical judgment, the combination of these antibiotics was still continued. After administration of these antibotics, rapid clinical improvement with signs short of breath, fever, cough was not observed and also the lung infiltrate was improved. The combination of meropenem and levofloxacin, may be a useful treatment option for hospital-acquired pneumonia related to Klebsiella pneumonia ESBL and also Acinetobacter baumanii, even these combination were resistance to Acinetobacter baumanii. Further research is also needed to clarify the effectiveness of meropenem and levofloxacin to treat Klebsiella pneumonia ESBL infection in the burn patient.
References
Leylabadlo H. E, Asgharzadeh M, Aghazadeh M. Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. Iranian journal of microbiology. 2015;7(5):226
Gomez R, Murray CK, Hospenthal DR. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg 2009 (208):348–54.
Boucher HW, Talbot GH, Bradley JS. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009 (48):1–12.
Keen, E.F. 3rd, Robinson, B.J., Hospenthal, D.R.. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns, 2010, 36: 819-25.
Paneru, T.P. Surveillance of Klebsiella pneumoniae and antibiotic resistance a retrospective and comparative study through a period in Nepal. Danish J. Med. Biol. Sci.,2015 : 29-36.
Bennett J, Robertson J, Hospenthal D. Impact of extended spectrum beta-lactamase producing Klebsiella pneumoniae infections in severely burned patients. J Am Coll Surg 2010 (211):391–9.
Jason W Bennett, Janelle L Robertson, Duane R Hospenthal, Seteven E Wolf, Kevin K Chung, Katrin Mende, et al. Impact of Extended Spectrum Beta-Lactamase Producing Klebsiella Pneuomia Infections in Severly Burned Patients. Journal American College of Surgeons.2010 : 391-398
Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis. 2013;19(1):133-36.
Ronat JB, Kakol J, Khoury MN, Berthelot M, Yun O, Brown V, et al. Highly Drug- Resistant Pathogens Implicated in Burn-Associated Bacteremia in an Iraqi Burn Care Unit. PLoS One. 2014;9(8).
Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2018;46(3):322–327.
Mandell SP, Pham T, Klein MB. Repeat hospitalization and mortality in older adult burn patients. J Burn Care Res. 2013;34(1):36–41
Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med. 2017;38(2):263–277
Tsai HY, Chen YH, Tang HJ. Carbapenems and Piperacillin/tazobactam For the Treatment of Bacteremia Caused by Extended-Spectrum Beta-lactamase-Producing Proteus mirabilis. Diagn Microbiol Infect Dis., 2014 : 222–226.
Wan-Ling Cheng, Po-Ren Hsuesh, Ching-Chi Lee, Chia-Wen Li, Ming-Ji Li, Chia-Ming Chang, et al, Bacterimia Pneumonia caused by Extended-Spectrum Beta-Lactamase-Producing Eschericia coli and Klebsiella pneumoniae : Appropropriatness of Empirical Treatment Matters. Journal of Microbiology, Immunology and Infection., 2016 (49) :208-215
Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother, 2012;13: 2319-2336.
Deylam Salehi M, Ferdosi-Shahandashti E, Yahyapour Y, Khafri S, Pournajaf A, Rajabnia R. Integron-Mediated Antibiotic Resistance in Acinetobacter baumannii Isolated from Intensive Care Unit Patients, Babol, North of Iran. Biomed Res Int 2017
Shoja S, Moosavian M, Rostami S, Farahani A, Peymani A, Ahmadi K, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii in patients with burn injuries. J Chin Med Assoc 2017; 80(4): 245-252
N. Rajkumari, N. V. John, P. Mathur, and M. C. Misra, “Antimicrobial resistance in Pseudomonas sp. causing infections in trauma patients: a 6 year experience from a south asian country,†Journal of Global Infectious Diseases, 2014, vol. 6, no. 4 : 182–185
Pogue J.M., Ortwine J.K., Kaye K.S. Optimal Usage of Colistin: Are We Any Closer? Clin. Infectious Dis. 2015;61:1778–1780.
.png)
